NASDAQ:SPRC SciSparc (SPRC) Stock Price, News & Analysis $6.10 +0.24 (+4.01%) Closing price 06/25/2026 03:58 PM EasternExtended Trading$6.10 0.00 (0.00%) As of 06/25/2026 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About SciSparc Stock (NASDAQ:SPRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SciSparc alerts:Sign Up Key Stats Today's Range$5.70▼$6.1650-Day Range$3.39▼$11.5452-Week Range$2.98▼$80.10Volume13,835 shsAverage Volume2.33 million shsMarket Capitalization$3.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline. The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function. By harnessing acoustic pressure waves, the TR100 aims to promote neurogenesis and synaptic plasticity without the need for surgical intervention. SciSparc has obtained CE marking for its tSWS platform in the European Union and is actively pursuing clinical trials in indications such as post‐stroke motor rehabilitation, treatment‐resistant depression and other neurological disorders. Serving both European and North American markets, SciSparc collaborates with academic institutions and clinical research centers to validate safety and efficacy in human subjects. Its Swiss headquarters oversees research and development, regulatory affairs and manufacturing partnerships, while its U.S. operations concentrate on clinical development and market access strategies. By integrating neuroscience research with advanced engineering, SciSparc aims to expand the availability of noninvasive neuromodulation therapies on a global scale.AI Generated. May Contain Errors. Read More SciSparc Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreSPRC MarketRank™: SciSparc scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSciSparc has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSciSparc has only been the subject of 1 research reports in the past 90 days.Read more about SciSparc's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioSciSparc has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.46% of the float of SciSparc has been sold short.Short Interest Ratio / Days to CoverSciSparc has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SciSparc has recently decreased by 94.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSciSparc does not currently pay a dividend.Dividend GrowthSciSparc does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for SciSparc this week, compared to 3 articles on an average week.Search Interest4 people have searched for SPRC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SciSparc insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,620.00 in company stock.Percentage Held by Insiders1.52% of the stock of SciSparc is held by insiders.Percentage Held by Institutions25.06% of the stock of SciSparc is held by institutions.Read more about SciSparc's insider trading history. Receive SPRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRC Stock News HeadlinesSciSparc Ltd. Ordinary Shares Stock Short Interest Rises to 66.94%June 10, 2026 | quiverquant.comQSciSparc Subsidiary NeuroThera Labs Closes Majority Acquisition of CliniQuantumJune 4, 2026 | tipranks.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid. | Behind the Markets (Ad)SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Completes Acquisition of 54% Stake in CliniQuantum Ltd.June 4, 2026 | quiverquant.comQSciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantumJune 4, 2026 | globenewswire.comSciSparc Ltd. Ordinary Shares (SPRC) SEC FilingsMay 30, 2026 | nasdaq.comSciSparc Ltd: SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantumMay 29, 2026 | finanznachrichten.deSciSparc jumps 150.8% as subsidiary wins conditional exchange approval for CliniQuantum dealMay 28, 2026 | quiverquant.comQSee More Headlines SPRC Stock Analysis - Frequently Asked Questions How have SPRC shares performed this year? SciSparc's stock was trading at $12.24 at the beginning of the year. Since then, SPRC shares have decreased by 50.2% and is now trading at $6.0950. How were SciSparc's earnings last quarter? SciSparc Ltd. (NASDAQ:SPRC) issued its quarterly earnings results on Wednesday, April, 29th. The company reported ($31.61) earnings per share for the quarter. The firm had revenue of $0.20 million for the quarter. When did SciSparc's stock split? SciSparc's stock reverse split on the morning of Wednesday, March 4th 2026.The 1-9 reverse split was announced on Monday, March 2nd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. How do I buy shares of SciSparc? Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SciSparc own? Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT). Company Calendar Last Earnings4/29/2026Today6/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 SPRC's financial health is in the Green zone, according to TradeSmith. SPRC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRC CIK1611746 Webscisparc.com Phone972-3717-5777FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick Ratio2.38 Sales & Book Value Annual Sales$860 thousand Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$12.93 per share Price / Book0.47Miscellaneous Outstanding Shares570,000Free Float557,000Market Cap$3.47 million OptionableNot Optionable Beta2.74 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SPRC) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersSpaceX IPO “cancelled”?SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...InvestorPlace | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe EPA just put a kill switch on Elon’s empireA federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredGrab it and keep itSimple Options Trading For Beginners is currently available as a free download - a guide normally priced at $2...Profits Run | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
